Press Releases

Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b/2a US/EU Clinical Trial

Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024* MONT SAINT-GUIBERT, Belgium – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing...

read more

NOVADIP is in the news

We are very proud to be in the news today. “Le tibia d’un enfant guéri grâce à une greffe osseuse 3D” Check out the links below. (23 min 30)

read more